知名网红、"下三路"研究专家，"峰哥亡命天涯"说过： "所有心理问题，都是性压抑。" 图源：微博 性压抑，本身就是一种复杂的社会心理状态，其中很大一部分并不是源自个体的身体问题，而是长期关系的单调和情感的疏离感造成的。 在这种背景下，人们自然会渴望一些能够调节亲密关系的"捷径"。 因此，人们便倾向于寻找那种看似低成本、低风险，却能带来高回报的外部方法。 而所谓的"高潮针"，正好切中了这种需求和痛点，被包装成了一种能快速修补情感裂痕、重燃亲密火花的"方案"。 "高潮针"到底是什么？ 今年上半年，一个所谓能让女性"一针就收获幸福"医美项目，被炒成了"爆款"。 图源：小红书 据了解，社交平台上充斥着各种夸张的宣传：从"重塑少女般的紧致感"到"秒变幸福女人"，价格从几千到几万元不等，仿佛花点钱就能解决性生活里的所 有不快。 图源：小红书 一个 19 岁女孩的哭泣自拍被拼贴进广告里，甚至挂上了黄色网站。 一些所谓的"真实分享"更是推波助澜：打针前自卑沮丧，打针后幸福满满，甚至连"水润""敏感"这些词都被反复渲染。 可真相却并不美丽，这背后不过是一场利用焦虑收割钱包的商业操作。 为了制造话题，商家不惜盗用他人照片。 图源 ...

Core Viewpoint - The article discusses the sudden popularity of the "climax needle," a cosmetic procedure aimed at enhancing female sexual pleasure, and highlights the associated marketing strategies and risks involved in its promotion [3][10]. Group 1: Market Dynamics - The "climax needle" gained significant attention on social media, leading to a surge in related medical beauty stocks, with companies like Tianyuan Co., Demei Chemical, and Bavi Co. seeing stock price increases of over 9% from April 25 to 27 [3]. - The domestic market for the "climax needle" reached 8.7 billion yuan in 2024, with projections to exceed 15 billion yuan in 2025 and potentially reach 80 billion yuan by 2030, reflecting a compound annual growth rate of over 35% [16][17]. Group 2: Marketing Strategies - The marketing of the "climax needle" follows a typical pattern in the medical beauty industry, leveraging emotional triggers such as "sexual anxiety" and "age crisis" to create a sense of urgency among women aged 30-45 [10][14]. - Social media platforms serve as the primary channels for promoting the "climax needle," with over 100,000 posts created to amplify its perceived benefits through user testimonials and before-and-after comparisons [10][14]. Group 3: Product and Safety Concerns - The "climax needle" involves injecting platelet-rich plasma (PRP) into the vaginal area, claiming to enhance sexual pleasure, but lacks substantial clinical trials to validate its effectiveness and safety [9][10]. - Medical professionals have reported various complications from the procedure, including infections, bleeding, and even severe cases leading to life-threatening conditions [9][10]. Group 4: Financial Implications - The "climax needle" boasts high profit margins, with a single injection costing around 10,000 yuan while the production cost is only about 1,000 yuan, resulting in a profit margin exceeding 80% [17]. - Companies are increasingly entering the "climax needle" market due to its lucrative nature, with significant interest from investors and businesses despite the lack of comprehensive clinical data supporting its claims [17][18].

Core Viewpoint - The "climax needle" concept stock experienced extreme volatility in the market, revealing the dark side of the medical beauty industry and the collusion between capital and human greed [2][3]. Group 1: Medical Device Misrepresentation - The "climax needle" is based on a medical device originally intended for orthopedic use, specifically a PRP preparation device, which was misrepresented in marketing as a vaginal injection for enhancing sexual pleasure [2][4]. - The approval process for PRP devices is stringent, requiring an average of 5.2 years for clinical trials and registration, yet significant regulatory loopholes exist [4]. Group 2: Market Reactions and Financial Implications - The stock of Bawei Co. surged by 2.3 billion yuan on April 26, only to plummet by 9% the next day, indicating a rapid shift from market enthusiasm to panic [3]. - The medical beauty sector's sales of PRP products reached over 1.4 billion yuan in 2023, highlighting the financial scale of the misrepresentation [5]. Group 3: Consumer Impact and Regulatory Response - Numerous cases of severe complications from the "climax needle" have been reported, including infections and permanent damage, underscoring the risks to consumers [7][12]. - Regulatory bodies are taking action, including the launch of a "medical beauty device cleansing action" and the implementation of a black-and-white list system for medical institutions [12]. Group 4: Proposed Solutions - Recommendations for addressing the issues include implementing traceability for medical devices, establishing ethical review committees for medical beauty technologies, and allowing collective lawsuits for consumers [9][10][11].

Core Viewpoint - The emergence of a cosmetic product called "climax needle" has gained significant attention, with reports indicating a surge in demand and appointments across multiple regions. However, medical professionals express concerns regarding its safety and efficacy, highlighting the lack of scientific backing and potential risks associated with its use [2][6][12]. Group 1: Product Overview - "Climax needle" involves injecting collagen into sensitive areas within the vagina to enhance sexual pleasure and climax, with prices ranging from several thousand to tens of thousands of yuan [2]. - A primary component of the "climax needle" is Platelet-rich plasma (PRP), which is derived from whole blood and is concentrated with platelets [3][4]. - PRP has been used in medical fields like orthopedics and dentistry since around 2000, primarily for wound healing and tissue repair [4][5]. Group 2: Efficacy and Evidence - The clinical evidence supporting PRP's effectiveness in various applications, including cosmetic procedures, is limited and often based on indirect studies, with some showing negligible results compared to placebo treatments [5][10]. - Despite claims of enhancing sexual experience through PRP injections at specific points, there is no high-level evidence to substantiate these assertions, and the results may vary significantly among individuals [9][10]. Group 3: Regulatory and Safety Concerns - PRP treatments have not been officially approved for cosmetic use in China, and the current regulatory framework does not adequately cover the practices of many private medical institutions offering these services [6][16]. - There are significant risks associated with the injection procedures, including potential infections, vascular damage, and severe complications such as embolism, particularly if performed by unqualified personnel [13][15][16]. - Some institutions have previously issued guidelines prohibiting certain high-risk injection practices, reflecting ongoing concerns about patient safety in the cosmetic industry [17].

Market Overview - A-shares experienced a volatile decline on April 28, with the Shanghai Composite Index falling by 0.2%, the Shenzhen Component Index down by 0.62%, and the ChiNext Index decreasing by 0.65% [3][4] - A total of 1,216 stocks rose, 48 stocks hit the daily limit up, while 4,110 stocks declined [4][5] - The total trading volume reached approximately 10,767.82 billion, with a trading volume of about 97,684.47 million [5] Sector Performance Power Sector - The power sector continued its strong performance, with stocks like Huadian Energy, Huadian Liaoning, and Three Gorges Water Conservancy hitting the daily limit up [6] - The State Council approved the construction of 10 nuclear power units, indicating a peak period for nuclear power construction in China, with 31 units already licensed and 13 units awaiting approval [6] Banking Sector - The banking sector showed resilience, with major banks such as China Construction Bank and Industrial and Commercial Bank of China reaching historical highs [8] Computing Power Sector - Computing power concept stocks saw a surge, with companies like Hengrun Co. and Dawi Technology hitting the daily limit up [10] Consumer Sector - The consumer sector faced a downturn, with food and retail stocks experiencing widespread adjustments, including companies like Youyou Food and Beibei Mei, which hit the daily limit down [12][14] - In the first quarter, Shanghai's total retail sales of consumer goods amounted to 4,057.45 billion, a year-on-year decrease of 1.1% [12] Notable Stock Movements - "Climax Needle" concept stocks plummeted, with Bawei Co. dropping over 13% and Demai Chemical down more than 5% [14] - The decline in "Climax Needle" stocks is attributed to concerns over the lack of scientific backing for the product, which claims to enhance female sexual function [14]

Core Viewpoint - The recent surge in interest around the "climax injection" is largely driven by marketing hype rather than genuine demand, with significant concerns regarding its safety and efficacy [1][2][3] Group 1: Product Overview - The "climax injection" is marketed as a procedure to enhance sexual pleasure by injecting collagen into sensitive areas, with prices ranging from thousands to tens of thousands of yuan [1] - A well-known product in this category is priced at "9800 yuan per injection; 19800 yuan for three treatments," but it is originally approved for use in bone fracture surgeries [2] Group 2: Regulatory and Safety Concerns - The product is classified as a third-class medical device, which is subject to strict regulatory oversight, and its use for purposes outside its approved indications raises serious safety concerns [2] - Experts have highlighted the potential risks associated with injecting into sensitive areas, including infection, bleeding, and nerve damage, as well as the lack of clinical trials supporting its efficacy [2][3] Group 3: Market Dynamics and Consumer Behavior - The marketing strategies employed by some institutions create a false sense of scarcity, leading consumers to believe that the injections are in high demand, which has been debunked by media investigations [1][3] - There is a growing need for regulatory bodies to enhance oversight of such products and practices, especially as they gain popularity and pose increasing risks to consumers [3]

Core Viewpoint - The "climax needle" concept has led to significant stock price fluctuations in related companies, highlighting the volatility and speculative nature of the medical beauty industry [1][4]. Group 1: Market Reaction - On April 28, after the opening of A-shares, stocks related to the "climax needle" concept experienced a collective decline, with Bawei Co. (837023) dropping over 9%, Demei Chemical (002054.SZ) down more than 7%, and Tianyuan Co. (002386.SZ) falling over 5% [1]. - Prior to the decline, these stocks had surged due to speculation surrounding the "climax needle," with some reaching their daily limit [1]. Group 2: Product Details - The "climax needle" is marketed as an injection of collagen at sensitive points within the female vagina, with prices ranging from thousands to tens of thousands of yuan [1]. - A specific product developed by Yuanxiang Biotechnology is priced at 9,800 yuan per injection and is classified as a "platelet-rich plasma preparation device" (PRP), which is a strictly regulated Class III medical device [3]. Group 3: Medical and Regulatory Insights - PRP technology involves extracting a patient's blood, processing it to concentrate platelets, and utilizing growth factors for tissue repair and regeneration [3]. - While PRP has been increasingly applied in the medical beauty sector, the National Medical Products Administration has not yet issued clear approvals for its use in facial injections, despite existing clinical literature [3][4]. - Experts have criticized the "climax needle" as lacking scientific support and warned of potential risks associated with its use, indicating a need for regulatory scrutiny in the medical beauty industry [1][4].

作者：毒舌师姐 来源：功夫财经（ID：kongfuf ） 01 前几天一众医美概念股的拉爆始终让人摸不着头脑，因为医美这个行业其实这几年来日子过得也 不太好。各种技术普及后，就是持续的在打价格战，利润越做越薄，怎么突突然然的发力了。直 到昨天，圈里流传出了一则消息。 以下文章来源于功夫财经 ，作者毒舌师姐 功夫财经 . 胡润百富榜影响力财经自媒体TOP10，透视财经事件，洞察商业趋势。 | | | | 小红书高潮针预约爆满 | | --- | --- | --- | --- | | | | 杭州、成都、珠海等多地女性预约开打高潮针 | | | 代码 | 名称 | 自由市值 | 主要逻辑 | | 002054 | 德美化工 | 20. 18亿 | 通过参股佛山德盛天林间接持有远想生物股权,后者旗下丽芙莎 品牌专注于女性私密健康领域,推出"高潮针"产品 | | 002386 | 天原股份 | 40. 19亿 | 通过参股佛山德盛天林间接持有远想生物股权,后者旗下丽芙莎 品牌专注于女性私密健康领域,推出"高潮针"产品 | | 688236 | 春立医疗 | 11.26亿 | 公司 PRP 产品包括富血小板血浆制备套 ...